Articles On Paradigm Biopharmaceuticals (ASX:PAR)

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

Paradigm Biopharmaceuticals (PAR) activates its first trial site in the United Kingdom for a third-phase trial of its Zilosul treatment for knee osteoarthritis The news comes after the company received UK regulatory and ethics approvals to...

Paradigm Biopharmaceuticals’ (ASX:PAR) investment relations guy Simon White is a bit different to your average biotech corporate gun for hire, given he’s actually tried the remedy he is promoting. A footballer with the AFL’s Carlton Footbal...

Paradigm Biopharmaceuticals (PAR) completes recruitment for its phase two clinical trial for treating knee osteoarthritis (OA) The phase two study aims to evaluate the treatment of pentosan polysulphate sodium (PPS) against a placebo in 6...

Wall Street had its worst ever start to the year in 50 years New data suggests the US economy is losing steam The ASX 200 is set to open higher today Wall Street tumbled again overnight by 1%, ending June as its worst ever start to the ye...

ShareCafeEvening Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket closed at session lows and had its worst day in two weeks in a broad-based rout. At the closing bell, the S&P/ASX 200 was almost 2 per cent or 132 p...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

Paradigm Biopharmaceuticals (PAR) receives approval from IP Australia for a key patent application for its knee osteoarthritis treatment The patent is for the treatment of bone marrow pathologies with PAR’s pentosan polysulphate sodium (PP...

ShareCafeLunch Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket has fallen for a second day and is on track to have its worst month since March 2020. At noon, the S&P/ASX 200 is 0.8 per cent or 52 points lower at 6...

30 Jun 2022 - A snapshot of the stocks on the move featuring, Paradigm Biopharmaceuticals (ASX:PAR), Estrella Resources (ASX:ESR), and Race Oncology (ASX:RAC).

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price isn’t letting the market weakness hold it back today. In morning trade, the biopharmaceutical company’s shares are up 20% to $1.15. Why is the Paradigm share price surging high...

ASX is set to open slightly higher today Major central bank bosses spoke overnight Wall Street ended the day mixed  Overnight, Wall Street wobbled as the most powerful central bankers in the world delivered a grim prediction. Speaking at...

Paradigm Biopharmaceuticals (PAR) receives an $8.2 million research and development tax incentive refund The clinical stage biopharmaceutical company was granted the refund as part of Australia’s R&D tax incentive scheme Paradigm quali...

ShareCafeEvening Report: 30 May, 2022 by Lauren Evans   The ASX 200 rose for a second successive day led by technology, materials and bank shares. At the closing bell, the index was 1.5 per cent or 104 points higher at 7,287, its best perfo...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is heading north during early afternoon trade on Monday. This follows the company’s latest announcement regarding a key appointment to its senior management team. At the time of wr...

ShareCafeLunch Report: 30 May, 2022 by Melissa Darmawan   Australian shares jumped to a three week high after a strong lead from Wall St. Every sector is rallying, bar utilities after news from AGL. The optimism is led by technology shares,...

Paradigm Biopharmaceuticals (PAR) appoints experienced pharmaceutical industry executive Marco Polizzi as its new CEO, effective July 1 With over 30 years of experience in the field, Mr Polizzi has a proven track record highlighted by seve...

ASX to open higher after a rally on Wall Street on Friday Bubs Australia has scored a significant export deal with the Biden government Australia’s GDP data to be released on Wednesday A strong surge on Wall Street on Friday is driving fu...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is racing higher during early afternoon trade on Thursday. This comes after the biopharmaceutical company provided an update on its pivotal phase 3 clinical trial. At the time of w...

Paradigm Biopharmaceuticals (PAR) begins dosing subjects in phase 3 of its clinical trial to test its Zilosul treatment for knee osteoarthritis pain The aim of the study is to measure the change in pain and function when receiving the inje...

Paradigm Biopharmaceuticals (ASX:PAR), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, says the first subjects have been randomised and dosed in the...

With Tuesday trade in the casket, the ASX Emerging Companies (XEC) index has closed about 1% lower, while the ASX 200 (XJO) benchmark index is down 0.5%, Everywhere markets fell, but for Paris, which has breathed a rich, garlic-scented merd...

Paradigm Biopharmaceuticals (PAR) granted Fast Track Designation by the US Food and Drug Administration (FDA) for its phase-three osteoarthritis development program The company’s planned phase-three clinical trial will investigate its pent...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is rocketing today, up 21.55% in early afternoon trading. Paradigm shares closed yesterday at $1.16 and are currently trading for $1.41. However, they climbed as high as $1.60 earl...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 0.5% to 7,449.9 points. Four ASX shares that are not letting that hold them back t...

Paradigm Biopharmaceuticals (ASX:PAR) has announced it has received regulatory and ethics approval from the UK regulator for a key late-stage clinical trial.

The US Patent Office (USTPO) has issued a final rejection notice for Paradigm Biopharmaceuticals' (ASX:PAR) key osteoarthritis patent application.

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AIZ)) - Air New Zealand ((ART)) - Airtasker ((APX)) - Appen ((ALX)) - Atlas Arteria ((AIA)) - Auckland International Airport ((AMI)) - Aurelia Metals ((ACL)) - Australia...

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

ASX director buying activity was fairly spread out over the past fortnight, with larger share sales few and far between.   Resources directors However one director who bucked that trend was Equus Mining (ASX:EQE) chairman Mark Lochtenberg...

World Overnight SPI Overnight 7235.00 + 10.00 0.14% S&P ASX 200 7332.50 – 76.30 – 1.03% S&P500 4532.76 – 44.35 – 0.97% Nasdaq Comp 14340.26 – 166.64 – 1.15% DJIA 35028.65 – 339.82 – 0.96% S&P500 VIX 23.85 + 1.06 4....

World Overnight SPI Overnight 7249.00 – 66.00 – 0.90% S&P ASX 200 7408.80 – 8.50 – 0.11% S&P500 4577.11 – 85.74 – 1.84% Nasdaq Comp 14506.90 – 386.86 – 2.60% DJIA 35368.47 – 543.34 – 1.51% S&P500 VIX 23.09 + 3.90 2...

World Overnight SPI Overnight 7340.00 + 22.00 0.30% S&P ASX 200 7417.30 + 23.40 0.32% S&P500 4662.85 + 3.82 0.08% Nasdaq Comp 14893.75 + 86.94 0.59% DJIA 35911.81 – 201.81 – 0.56% S&P500 VIX 19.19 – 1.12 – 5.51%...

Highlights Clinuvel completes enrolment in its world-first study of stroke with afamelanotide as treatment for arterial ischaemic stroke (AIS) patients. All patients under consideration showed good tolerance to the treatment without an...

Paradigm Biopharmaceuticals (PAR) doses its first two subjects with Zilosul in its phase three clinical trial for pain associated with knee osteoarthritis (kOA) The study will evaluate the dose and treatment effect of injectable pentosan p...

The company hopes to address vast unmet need in osteoarthritis patients across the developed world, where an estimated 120 million people are expected to be afflicted with this painful disease by 2030.

US inflation data came in at historic highs overnight, rising by 7% year-on-year — the highest level since 1982. Core inflation also came in slightly above expectations at 5.5%, although the monthly pace of headline inflation growth slowed...

Paradigm Biopharmaceuticals (PAR) says it has received positive interim data from a phase 2 pilot study of pentosan polysulfate sodium (PPS) for the treatment of mucopolysaccharidosis type I (MPS-I) Paradigm’s study enrolled three patients...

PPS was well tolerated with no serious adverse events reported over a 24-week period and there were meaningful improvements in pain, function and activities of daily living while an overall improvement in quality of life was observed in all...

Paradigm Biopharmaceuticals (PAR) sees a shake up to its leadership board, with CEO Paul Rennie transitioning from Managing Director to a non-executive role as Chairman In the non-executive role, Paul Rennie will focus on the direction of...

The company has initiated a search for a new CEO with global pharma experience and has already identified a number of potential candidates.

Dr Christian Reiter’s "extensive knowledge base and experience with PPS will be great value to Paradigm’s R&D projects in developing new pipeline and second-generation products, as well as Paradigm’s OA and MPS programs," Paradigm CSO D...

World Overnight SPI Overnight 7456.00 + 9.00 0.12% S&P ASX 200 7452.20 – 4.70 – 0.06% S&P500 4701.70 + 4.17 0.09% Nasdaq Comp 15982.36 + 10.77 0.07% DJIA 36432.22 + 104.27 0.29% S&P500 VIX 17.22 + 0.74 4.49% US 1...

After conducting market research across four major global markets to determine the willingness of patients to pay for and doctors to prescribe Zilosul®, the company found broad approval for the treatment, suggesting an acceptable market pri...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

On Wednesday I looked at three ASX shares brokers have given buy ratings to this week. Unfortunately, not all shares are in favour with them right now. Three ASX shares that have just been given sell ratings by brokers are listed below. He...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another gain. At the time of writing, the benchmark index is up 0.3% to 7,415.7 points. Four ASX shares that have failed to follow the market’s lead today are...